For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Cullinan Therapeutics Inc’s stock clocked out at $15.63, down -0.19% from its previous closing price of $15.66. In other words, the price has decreased by $-0.19 from its previous closing price. On the day, 0.95 million shares were traded. CGEM stock price reached its highest trading level at $16.32 during the session, while it also had its lowest trading level at $15.29.
Ratios:
To gain a deeper understanding of CGEM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.07 and its Current Ratio is at 17.07. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On February 15, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $30.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 01 ’24 when Savill Corrine sold 40,000 shares for $16.18 per share. The transaction valued at 647,200 led to the insider holds 165,990 shares of the business.
Savill Corrine sold 40,000 shares of CGEM for $563,600 on Jan 29 ’24. The Chief Business Officer now owns 165,990 shares after completing the transaction at $14.09 per share. On Jan 23 ’24, another insider, Savill Corrine, who serves as the Chief Business Officer of the company, sold 21,316 shares for $12.46 each. As a result, the insider received 265,597 and left with 165,990 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGEM now has a Market Capitalization of 673115328 and an Enterprise Value of 211123008.
Stock Price History:
The Beta on a monthly basis for CGEM is 0.36, which has changed by 0.46629214 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, CGEM has reached a high of $20.62, while it has fallen to a 52-week low of $7.64. The 50-Day Moving Average of the stock is -9.44%, while the 200-Day Moving Average is calculated to be 30.71%.
Shares Statistics:
It appears that CGEM traded 510.11K shares on average per day over the past three months and 830660 shares per day over the past ten days. A total of 42.90M shares are outstanding, with a floating share count of 26.36M. Insiders hold about 38.80% of the company’s shares, while institutions hold 56.13% stake in the company. Shares short for CGEM as of 1711584000 were 1436008 with a Short Ratio of 2.82, compared to 1709164800 on 694101. Therefore, it implies a Short% of Shares Outstanding of 1436008 and a Short% of Float of 4.099999700000001.
Earnings Estimates
The current assessment of Cullinan Therapeutics Inc (CGEM) involves the perspectives of Compugen Ltd. analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $25.05, with high estimates of $45.75 and low estimates of $15.63.
